Acurx Pharmaceuticals, Inc. ACXP

Acurx Pharmaceuticals Q2 2026 earnings call highlights FDA signals of potential regulatory progress for ibezapolstat in C. difficile infection treatment. FDA signals point to likely regulatory progress that can materially shift approval timeline and investor outlook.

Acurx Pharmaceuticals received FDA conditional acceptance and USPTO trademark allowance for the brand name of Ibezapolstat. FDA conditional acceptance plus trademark allowance for Ibezapolstat advances regulatory and branding steps toward commercialization.

Acurx Pharmaceuticals held its Q2 2026 earnings call covering quarterly financial results, operational updates and forward outlook. Quarterly earnings calls deliver financial metrics and guidance that can shift near-term investor sentiment and valuation.

Acurx Pharmaceuticals reported second quarter 2026 financial results and issued a business update. Quarterly results and business updates deliver financial metrics and operational details that can shift near-term investor views without altering long-term strategy.

Japan and Mexico patent offices granted Acurx Pharmaceuticals new patents for DNA Polymerase IIIC inhibitor antibiotics. Patent grants expand ACXP intellectual property protection in additional markets for its core antibiotic technology.

Acurx Pharmaceuticals partners with Leiden University Medical Center to advance development of DNA Polymerase IIIC Inhibitor Antibiotics. Academic partnership advances core antibiotic pipeline with moderate innovation effects but limited near-term financial or market shifts.

FDA provides further guidance to Acurx on ibezapolstat clinical program, including potential single Phase 3 registration trial design supporting both C. difficile treatment and reduction of recurrence. FDA guidance enables potential single Phase 3 trial that could accelerate ibezapolstat approval and market entry.

Acurx Pharmaceuticals announces scientific poster presentation of ibezapolstat microbiome preservation data in multiply-recurrent C. difficile infection. Poster data on ibezapolstat microbiome effects may support competitive positioning for ACXP's lead candidate.

Acurx Pharmaceuticals highlighted FDA's new guidance on Clostridioides difficile infection treatments that may accelerate approval for its antibiotic ibezapolstat. FDA guidance update could shorten ibezapolstat approval timeline and improve company outlook.

Acurx Pharmaceuticals, Inc. (ACXP) released Q1 2026 earnings call summary detailing financial results, pipeline progress, and business updates. Q1 2026 earnings summary reveals financial performance and strategic updates critical to ACXP's valuation and investor outlook.

Acurx Pharmaceuticals, Inc. (ACXP) reported first quarter 2026 financial results and provided a business update. Quarterly results and business updates influence financial performance and investor sentiment for biotech firms.

Acurx Pharmaceuticals, Inc. (ACXP) announced the closing of a registered direct offering for up to $7.1 million, priced at-the-market under Nasdaq rules, with proceeds intended for general corporate purposes including clinical development of lead antibiotic candidate. Securing $7.1 million in funding significantly strengthens ACXP's balance sheet, supports ongoing clinical trials, and enhances short-to-medium term operational runway amid biotech funding challenges.

Korean Patent Office grants Acurx Pharmaceuticals new patent for DNA Polymerase IIIC inhibitors, strengthening IP protection for its antibiotic program targeting Gram-positive bacteria including MRSA. New Korean patent enhances Acurx's global IP portfolio for its novel antibiotic mechanism, supporting clinical advancement and potential market exclusivity.

Acurx Pharmaceuticals Inc (ACXP) Q4 2025 earnings call highlights financial growth and key developments. Q4 2025 earnings call reveals financial growth, signaling significant positive impact on ACXP's trajectory and investor sentiment.

Acurx Pharmaceuticals, Inc. (ACXP) reported full-year and fourth quarter financial results and provided a business update. Full-year and quarterly results with business update moderately influence financial performance and investor sentiment.

Acurx Pharmaceuticals announces new clinical trial program for Ibezapolstat in patients with recurrent C. difficile infection (CDI), with potential to shift paradigms in CDI treatment and prevention. New Ibezapolstat trial program for recurrent CDI represents a major clinical advancement that could significantly enhance Acurx's pipeline value and investor sentiment.

Acurx Pharmaceuticals, Inc. (ACXP) secures a new US patent for its DNA Polymerase IIIC inhibitors, bolstering intellectual property protection for its antibiotic development program targeting Gram-positive bacteria including MRSA. New US patent strengthens ACXP's IP portfolio for its core antibiotic technology, enhancing competitive edge and investor sentiment.

Acurx Pharmaceuticals, Inc. has been granted a new patent by the USPTO for its DNA Polymerase IIIC inhibitors. This patent is expected to enhance the company's intellectual property portfolio and support its ongoing development of innovative therapies targeting bacterial infections. The patent could provide a competitive edge in the pharmaceutical market, potentially leading to new treatment options and revenue streams. The new patent is likely to significantly impact Acurx's future by enhancing its product offerings and competitive positioning in the market.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is projected to reach breakeven in the medium term despite currently operating at a loss. The company is focused on developing its antibiotic treatments and has made progress in its clinical trials, which could enhance its financial outlook. Investors are optimistic about the potential for future profitability as the company advances its product pipeline. The expected breakeven point indicates a moderately noticeable influence on financial performance and market sentiment.

Acurx Pharmaceuticals, Inc. (ACXP) has shown notable performance in the medical sector this year, outpacing many of its peers. The company's advancements in antibiotic development and strategic initiatives have contributed to its positive market sentiment. Investors are closely monitoring ACXP's progress as it navigates the competitive landscape and seeks to capitalize on growth opportunities. Acurx's advancements in antibiotic development may moderately influence its financial performance and competitive positioning.

Acurx Pharmaceuticals, Inc. (ACXP) is featured in New to The Street Show #702, airing today on Bloomberg at 6:30 PM EST. The segment highlights the company's advancements and strategic initiatives in the pharmaceutical sector, aiming to enhance investor awareness and market presence. The show may moderately influence investor sentiment and awareness of Acurx's developments.

Acurx Pharmaceuticals, Inc. has received an innovative research grant from Health~Holland for the development of DNA Pol IIIC inhibitors in collaboration with Leiden University Medical Center. This funding aims to advance research in this area, potentially leading to new therapeutic options. The grant represents a significant strategic opportunity for Acurx Pharmaceuticals to enhance its research capabilities and product pipeline.

Acurx Pharmaceuticals, Inc. (ACXP) is featured in the landmark Show #700 of 'New to The Street,' airing today at 6:30 PM ET on Bloomberg Television. The show highlights the company's advancements and future prospects in the pharmaceutical industry, aiming to inform investors and the public about its innovative approaches. The show may enhance visibility and market sentiment but is unlikely to significantly alter the company's trajectory.

Acurx Pharmaceuticals, Inc. reported its third quarter results, highlighting progress in its clinical programs and financial performance. The company continues to advance its lead product candidate, ACX-362E, targeting bacterial infections. Acurx also provided updates on its strategic initiatives and future plans, emphasizing its commitment to addressing unmet medical needs in the antibiotic space. The updates on clinical programs and financial performance indicate a moderately noticeable influence on the company's future trajectory.

Acurx Pharmaceuticals, Inc. announced the publication of research in Nature Communications highlighting its innovative approach to targeting DNA polymerase IIIC in Gram-positive priority pathogens. This research underscores the company's commitment to addressing antibiotic resistance and developing effective treatments for serious infections caused by these pathogens. The publication of significant research findings could enhance Acurx's competitive positioning and investor sentiment regarding its antibiotic development pipeline.

Acurx Pharmaceuticals, Inc. presented new data on its DNA pol IIIC inhibitor antibiotics at the IDWeek 2025 Scientific Conference, highlighting a potential class effect of gut microbiome selectivity. This research suggests that the antibiotics may selectively target harmful bacteria while preserving beneficial gut microbiota, which could enhance treatment outcomes and reduce side effects associated with traditional antibiotics. The presentation of new data indicating gut microbiome selectivity could significantly influence Acurx's competitive positioning and market perception.

Acurx Pharmaceuticals, Inc. (ACXP) is participating in New to The Street's Accredited Investor Event on October 21-22 at Hudson Yards, NYC. This event aims to connect investors with emerging companies, providing a platform for Acurx to showcase its developments and engage with potential investors. Participation in investor events can moderately influence market sentiment and visibility for Acurx, but the overall impact on its trajectory is expected to be limited.

Acurx Pharmaceuticals, Inc. has been granted a patent by the Australian Patent Office for its DNA Polymerase IIIC inhibitors. This patent is expected to enhance the company's intellectual property portfolio and support its ongoing development of novel antibiotics targeting resistant bacterial infections. The patent grant is a significant strategic move that could enhance Acurx's competitive position and investor sentiment in the antibiotic market.

Acurx Pharmaceuticals, Inc. received a positive opinion from the European Medicines Agency (EMA) regarding its Pediatric Investigation Plan for Ibezapolstat, a treatment for children with Clostridium difficile infection. This opinion is a significant step towards developing the drug for pediatric use, potentially expanding its market and addressing an unmet medical need in this demographic. The positive EMA opinion could significantly enhance Acurx's market position and growth potential in pediatric therapeutics.

Acurx Pharmaceuticals, Inc. has partnered with New to The Street for long-form interviews, national TV commercials, earned media, and accredited investor events. This collaboration aims to enhance the company's visibility and outreach to potential investors and the public. The partnership is expected to moderately influence Acurx's market presence and investor engagement.